TY - JOUR T1 - Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study JF - medRxiv DO - 10.1101/2020.12.13.20248146 SP - 2020.12.13.20248146 AU - Kathryn Peebles AU - John E. Mittler AU - Steven M. Goodreau AU - James T. Murphy AU - Molly C. Reid AU - Neil Abernethy AU - Geoffrey S. Gottlieb AU - Ruanne V. Barnabas AU - Joshua T. Herbeck Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/14/2020.12.13.20248146.abstract N2 - Pathogen populations can evolve in response to selective pressure from vaccine-induced immune responses. For HIV, models predict that viral adaptation, either via strain replacement or selection on de novo mutation, may rapidly reduce the effectiveness of an HIV vaccine. We hypothesized that behavioral risk compensation after vaccination may accelerate the transmission of vaccine resistant strains, increasing the rate of viral adaptation and leading to a more rapid decline in vaccine effectiveness. To test our hypothesis, we modeled: a) the impact of risk compensation on rates of HIV adaptation via strain replacement in response to a partially effective vaccine; and b) the combined impact of risk compensation and viral adaptation on vaccine-mediated epidemic control. We used an agent-based epidemic model that was calibrated to HIV-1 trends in South Africa, and includes demographics, sexual network structure and behavior, and within-host disease dynamics. Our model predicts that risk compensation can increase the rate of HIV viral adaptation in response to a vaccine. In combination, risk compensation and viral adaptation can, under certain scenarios, reverse initial declines in prevalence due to vaccination, and result in HIV prevalence at 15 years equal to or greater than prevalence without a vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the U.S. National Institutes of Health grants R01-AI108490 (SMG, JTH, JEM), R01-AI150467 (JTH), R21-HD075662 (SMG), R01-HD068395 (provided support to SMG), and the University of Washington student technology fee (https://uwstf.org) (support for the Hyak super-computer system used in this research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modeling study and no IRB approval was needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll model code is freely available on github.com/EvoNetHIV. https://github.com/EvoNetHIV ER -